Orchard Therapeutics plc (NasdaqGM: ORTX)
Health Care · Biotechnology · GB
$—
— today · — 1Y
Orchard Therapeutics plc (NasdaqGM: ORTX) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Orchard Therapeutics plc across four factors: quality 26/100. Its strongest factor is quality.
ORTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $21.84M
- P/E
- —
- EPS
- -4.24
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 166
- Next earnings
- —
About Orchard Therapeutics plc
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
- ISIN
- US68570P2002
- Founded
- 2015
- Listed since
- Oct 31, 2018
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.21 | +0.09% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.32 | +0.45% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.34 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $549.06 | +0.18% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $826.41 | -0.91% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $136.79 | -5.71% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.